Table 1 Patient characteristics at baseline for the discovery and the three replication cohorts.

From: 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation

Characteristic

Discovery (n = 143)

Replication I (n = 115)

Replication II (n = 107)

Replication III (n = 143)

Study center

Regensburg

Regensburg

Regensburg

Hamburg

Vitamin D3 suppl.a

High-dose

High-dose

Moderate

None

Male sex

84 (58.7%)

75 (65.2%)

74 (69.2%)

94 (65.7%)

median age (range)[yr]

56 (26–70)

56 (19–69)

52 (19–71)

58 (18–75)

Diagnosis

  Aplastic anemia

2 (1.4%)

5 (4.3%)

2 (1.9%)

2 (1.4%)

  Acute leukemia

76 (53.1%)

62 (53.9%)

55 (51.4%)

47 (32.9%)

  Morbus Hodgkin

5 (3.5%)

0

1 (0.9%)

0

  MDS

17 (11.9%)

16 (13.9%)

12 (11.2%)

25 (17.5%)

  MPN

4 (2.8%)

12 (10.4%)

6 (5.6%)

27 (18.9%)

  NHL

34 (23.8%)

18 (15.7%)

26 (24.3%)

20 (14.0%)

  PMF

5 (3.5%)

2 (1.7%)

4 (3.7%)

22 (15.4%)

Late tumor stageb

75 (58.6%)

74 (64.3%)

65 (60.7%)

101 (70.6%)

Unrelated donor

102 (71.3%)

81 (70.4%)

83 (77.6%)

108 (75.5%)

ATG before HSCT yes

102 (71.3%)

81 (70.4%)

83 (77.6%)

134 (93.7%)

Standard conditioningc

13 (9.4%)

20 (17.4%)

17 (15.9%)

35 (24.5%)

Steroids ≥1 mg/kgd

65 (53.3%)

52 (45.2%)

55 (51.4%)

74 (51.7%)

Karnofsky score <90e

46 (33.3%)

53 (46.1%)

16 (15.0%)

94 (66%)

  1. Shown are characteristics of the 508 patients in the vitamin D study. Stated are number of participants and percentages, if not indicated otherwise.
  2. suppl. supplementation, yr years, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm, NHL non-Hodgkin lymphoma, PMF primary myelofibrosis, HSCT hematopoietic stem cell transplantation, ATG antithymocyte globulin.
  3. aType of vitamin D3 supplementation in the different cohorts: high-dose supplementation (50.000 IU p.o. at start, followed by 10.000 IU/d p.o.) was adjusted for patients with 25-hydroxyvitamin-D3 levels higher than 200 nmol/L; moderate supplementation: 1.000–5.000 IU/d p.o.
  4. bAt enrollment (before HSCT), no tumor stage grading available for 15 patients from discovery and for 1 patient from replication data I, classification according to EBMT risk score [50].
  5. cMissing information on conditioning for discovery cohort from five patients.
  6. dMissing information on steroid treatment for discovery cohort, replication cohort I, and replication cohort II from 21, 5, or 7 patients, respectively.
  7. eMissing information on Karnofsky performance score for discovery cohort, replication cohort I, replication cohort II, and replication cohort III from 5, 8, 4, or 11 patients, respectively.
Back to article page